The overall response rate (84.4% vs 67.5%; p=0.02), median progression free survival (6.9 months vs 4.8 months; p=0.003) and median overall survival (9.4 months vs 12.8 month; p=0.002) were significantly higher in the cisplatin/irinotecan group compared to the cisplatin/etoposide group.
Overall and progression-free survivalr
© N Engl J Med 2002
There was no significant difference in response rates (48% vs 43.6%), median time to progression (4.1 months vs 4.6 months; p=0.37) or median overall survival (9.3 months vs 10.2 months; p=0.74) between the cisplatin/irinotecan and cisplatin/etoposide groups.
Time to progression and overall survivalr
© J Clin Oncol 2006
In the meta-analysis, the pooled hazard ration for overall survival was found to favour irinotecan-platinum doublet (HR=0.81, 95% CI =0.71-0.93; p=0.003) with no significant heterogeneity (p=0.081). Progression free survival was similar between the two regimens (HR=0.90; 95%CI: 0.76-1.07, p=0.227) but with significant heterogeneity (p=0.012). There was no difference in overall response rate (RR=1.04, 95% CI=0.95-1.13, p=0.378) and test for heterogeneity was not significant (p=0.190).
© J Thorac Oncol 2012